Core Viewpoint - The report emphasizes the importance of capturing structural opportunities in the pharmaceutical sector, particularly focusing on medical/healthcare AI and stocks with positive fundamental changes [1] Market Performance - The Shanghai and Shenzhen 300 index rose by 0.36%, while the pharmaceutical and biological sector declined by 0.81%, ranking 21st among 31 primary sub-industries this week [1] - The medical services sector increased by 0.22%, while the chemical pharmaceuticals, biological products, medical devices, traditional Chinese medicine, and pharmaceutical commerce sectors fell by 0.54%, 0.89%, 1.07%, 1.75%, and 2.68% respectively [1] Investment Opportunities - The pharmaceutical market is showing clear segmentation, with AI healthcare, small nucleic acid-related stocks that have recently corrected, and stocks with marginal fundamental changes and lighter institutional holdings performing well [1] - The pharmaceutical sector, combining technology and consumer attributes, is expected to continue exhibiting structural trends amid market rotations [1] - The innovative drug sector has experienced a significant rise followed by a correction over the past year, with valuations generally considered reasonable compared to early 2025 levels [1] Recommended Focus Areas - It is advised to pay attention to specific sub-sectors such as small nucleic acids, in vivo CAR, ADC, second-generation IO, and PROTAC, as well as companies with marginal fundamental changes that are likely to realize sustained performance [1] - The medical/healthcare AI+ sector is highlighted as a recently popular direction, suggesting a focus on leading companies in this field, as well as those with non-pharmaceutical/healthcare AI+ core businesses that are actively embracing related technologies and expected to realize valuation flexibility in the short to medium term [1] - In the consumer aspect, with 2025 performance forecasts largely reflected in current stock prices, attention is recommended on traditional Chinese medicine and medical beauty sectors that are actively expanding their product offerings, as well as the medical services sector that has undergone long-term adjustments [1]

Core Viewpoint - The pharmaceutical sector, characterized by both technology and consumer attributes, is expected to continue exhibiting structural trends amid market fluctuations, with a focus on innovative drug segments and emerging technologies like AI in healthcare [1][2]. Group 1: Market Performance - The Shanghai and Shenzhen 300 index rose by 0.36%, while the pharmaceutical and biological sector declined by 0.81%, ranking 21st among 31 primary sub-industries [2][4]. - The medical services sector increased by 0.22%, while chemical pharmaceuticals, biological products, medical devices, traditional Chinese medicine, and pharmaceutical commerce saw declines of 0.54%, 0.89%, 1.07%, 1.75%, and 2.68% respectively [2][4]. Group 2: Investment Recommendations - Companies are advised to focus on sectors with positive fundamental changes and light institutional holdings, particularly in the AI healthcare and small nucleic acid segments, which have shown strong performance [2][3]. - The report suggests monitoring companies that are not primarily in the pharmaceutical/medical AI+ sector but are actively adopting related technologies with potential for short-term valuation flexibility [2]. Group 3: In Vivo CAR Developments - Multiple clinical studies for in vivo CAR are expected to reach major endpoints within the year, particularly those targeting autoimmune indications, indicating significant potential for this cutting-edge technology [3][4]. - Abbvie's acquisition of Capstan for $21 billion is highlighted, with its core pipeline expected to reach major clinical endpoints soon, focusing on safety and immune response indicators, which could pave the way for further development in autoimmune indications [4]. Group 4: Overall Sector Analysis - The pharmaceutical sector has yielded a return of 2.44% since early 2026, outperforming the Shanghai and Shenzhen 300 index by 1.79 percentage points [4].

Core Insights - The report emphasizes the importance of capturing structural opportunities in the pharmaceutical sector, particularly focusing on in vivo CAR technology and its potential advancements in autoimmune indications [3][4] - The report highlights the recent performance of the pharmaceutical sector, noting a 2.44% return since the beginning of 2026, outperforming the CSI 300 index by 1.79 percentage points [5] Market Performance - The CSI 300 index increased by 0.36% this week, while the pharmaceutical and biological sector declined by 0.81%, ranking 21st among 31 primary sub-industries [3][5] - Specific segments within the pharmaceutical sector showed varied performance, with medical services up by 0.22%, while chemical pharmaceuticals, biological products, medical devices, traditional Chinese medicine, and pharmaceutical commerce saw declines ranging from 0.54% to 2.68% [3][5] In vivo CAR Developments - Multiple clinical studies for in vivo CAR are expected to reach major endpoints within the year, particularly those targeting autoimmune indications, which could signify significant advancements in the field [4] - The report notes that Abbvie's acquisition of Capstan for $2.1 billion is pivotal, as its core pipeline is anticipated to reach key clinical milestones soon, focusing on safety and immune response indicators [4] Investment Recommendations - The report suggests focusing on stocks with marginal changes in fundamentals and lighter institutional holdings, particularly in sectors like small nucleic acids, in vivo CAR, ADC, second-generation IO, and protac [3] - It also recommends monitoring companies that are not primarily in the medical/healthcare AI+ sector but are actively adopting related technologies, as they may offer short-term valuation flexibility [3]